Ignite Creation Date:
2024-05-06 @ 8:23 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02726854
Status:
UNKNOWN
Last Update Posted:
2016-12-02
First Post:
2016-03-16
Brief Title:
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
Sponsor:
First Affiliated Hospital Xian Jiaotong University
Organization:
First Affiliated Hospital Xian Jiaotong University
Study Overview
Official Title:
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer Phase II Clinical Study of Open Arm
Status:
UNKNOWN
Status Verified Date:
2016-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Apslpanc
Brief Summary:
The main research purpose Evaluation of objective response Apatinib second-line treatment of advanced pancreatic cancer ORR and the rate of progression free survival PFS
Objective to study the objective and exploratory secondary research To observe the Apatinib in second line treatment of advanced pancreatic cancer disease control rate DCR patients with overall survival OS benefit treatment effects on quality of life QOL score and drug safety evaluation To investigate the relationship of apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptorVEGFR in the serum
Objective to study the objective and exploratory secondary research To observe the Apatinib in second line treatment of advanced pancreatic cancer disease control rate DCR patients with overall survival OS benefit treatment effects on quality of life QOL score and drug safety evaluation To investigate the relationship of apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptorVEGFR in the serum
Detailed Description:
The purpose of this study is to determine what effects apatinib has on advanced pancreatic cancer patients after failure of first-line chemotherapy cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer patientsTo investigate the relationship between apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptorVEGFR in the serum
This study choose the First Affiliated Hospital of Xian JiaoTong University were unable to tolerate the failure of first-line chemotherapy for second-line chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer patients as the research object the clinical data of clinical subjects age and sex Eastern Cooperative Oncology Group ECOG score tumor stage pathological type pathological grading giving apatinib treatment during the treatment of blood monitoring in patients with CA199 levels imaging findings assessment of tumor related symptoms and adverse events and the expression of VEGFR in blood was measured by ELISA method the curative effect evaluation of the end of the 2 cycle of treatment patients with effective evaluation to oral apatinib through the statistical analysis of the data of complete remission CR or partial remission PR the rate of progression free survival PFS expression of CA199 content in serum and serum VEGFR levels of the relevant indicators Explore Apatinib for the curative effect and safety of the second-line treatment of advanced pancreatic cancer and to explore the relationship between the serum VEGF expression level
This study choose the First Affiliated Hospital of Xian JiaoTong University were unable to tolerate the failure of first-line chemotherapy for second-line chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer patients as the research object the clinical data of clinical subjects age and sex Eastern Cooperative Oncology Group ECOG score tumor stage pathological type pathological grading giving apatinib treatment during the treatment of blood monitoring in patients with CA199 levels imaging findings assessment of tumor related symptoms and adverse events and the expression of VEGFR in blood was measured by ELISA method the curative effect evaluation of the end of the 2 cycle of treatment patients with effective evaluation to oral apatinib through the statistical analysis of the data of complete remission CR or partial remission PR the rate of progression free survival PFS expression of CA199 content in serum and serum VEGFR levels of the relevant indicators Explore Apatinib for the curative effect and safety of the second-line treatment of advanced pancreatic cancer and to explore the relationship between the serum VEGF expression level
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None